Yahoo Finance • last year
VIENNA, Va., November 16, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 2,490,000 shares of its common st... Full story
Yahoo Finance • 2 years ago
VIENNA, Va., April 28, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public off... Full story
Yahoo Finance • 2 years ago
Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch VIENNA, Va., August 08, 2022--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the appoin... Full story